Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.64 |
| ▸ | HTR6 | P50406 | 15/20 | 0.53 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7561915 | 0.79 | HTR2A (0.66) | HTR2AHTR6SCN9ATAAR1 | |
| SCHEMBL5738832 | 0.79 | POLB (0.59) | HTR2A | |
| SCHEMBL28806593 | 0.79 | POLB (0.41) | HTR2AHTR6 | |
| SCHEMBL332959 | 0.78 | HTR2A (1.00) | HTR2AHTR6SCN9A | |
| SCHEMBL6787250 | 0.78 | HTR2A (0.64) | HTR2AHTR6SCN9ATAAR1 | |
| SCHEMBL25166949 | 0.78 | HTR2A (0.64) | HTR2AHTR6SCN9ATAAR1OPRM1 | |
| SCHEMBL106451 | 0.78 | HTR2A (0.64) | HTR2AHTR6SCN9ATAAR1OPRM1 | |
| SCHEMBL8374898 | 0.77 | HTR2A (0.58) | HTR2AHTR6SCN9ATAAR1OPRM1 | |
| Hydrochloric Acid SCHEMBL9695585 | 0.76 | HTR2A (0.62) | HTR2AHTR6SCN9ATAAR1OPRM1 | |
| Ammonia Solution, Strong SCHEMBL28037069 | 0.76 | HTR2A (0.62) | HTR2AHTR6SCN9ATAAR1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4428880-A | Azepino[4,5-d]indole derivatives and preparation thereof | S.A. OMNICHEM (BE) | 1984-01-31 | — | — | US | claimed |
| US-20250354108-A1 | METHODS FOR PRODUCING MONOTERPENE INDOLE ALKALOIDS | UNIV DANMARKS TEKNISKE (DK) | 2025-11-20 | — | — | US | disclosed |
| EP-4526426-A2 | METHODS FOR PRODUCING MONOTERPENE INDOLE ALKALOIDS | Danmarks Tekniske Universitet (DK) | 2025-03-26 | — | — | EP | disclosed |
| US-20240417764-A1 | METHODS FOR THE PRODUCTION OF TRYPTOPHANS, TRYPTAMINES, INTERMEDIATES, SIDE PRODUCTS AND DERIVATIVES | MIAMI UNIVERSITY | 2024-12-19 | — | — | US | disclosed |
| EP-4426676-A2 | METHODS FOR THE PRODUCTION OF TRYPTOPHANS, TRYPTAMINES, INTERMEDIATES, SIDE PRODUCTS AND DERIVATIVES | MIAMI UNIVERSITY (US) | 2024-09-11 | — | — | EP | disclosed |
| WO-2023081837-A9 | METHODS FOR THE PRODUCTION OF TRYPTOPHANS, TRYPTAMINES, INTERMEDIATES, SIDE PRODUCTS AND DERIVATIVES | MIAMI UNIVERSITY (US) | 2024-03-14 | — | — | WO | disclosed |
| WO-2023222879-A2 | METHODS FOR PRODUCING MONOTERPENE INDOLE ALKALOIDS | DANMARKS TEKNISKE UNIVERSITET (DK) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023081837-A2 | METHODS FOR THE PRODUCTION OF TRYPTOPHANS, TRYPTAMINES, INTERMEDIATES, SIDE PRODUCTS AND DERIVATIVES | MIAMI UNIVERSITY (US) | 2023-05-11 | — | — | WO | disclosed |
| US-20210353763-A1 | SITE-SPECIFIC COVALENT CHEMICAL LIGATION TO MONOCLONAL AND POLYCLONAL IMMUNOGLOBULIN | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-11-18 | — | — | US | disclosed |
| US-10588982-B2 | Site-specific covalent chemical ligation to monoclonal and polyclonal immunoglobulin | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-03-17 | — | — | US | disclosed |
| WO-2016164843-A1 | SITE-SPECIFIC COVALENT CHEMICAL LIGATION TO MONOCLONAL AND POLYCLONAL IMMUNOGLOBULIN | Lac Diana (US) | 2016-10-13 | — | — | WO | disclosed |
| CN-102014897-B | Compound, compositions and its preparation method | SIGNUM BIOSCIENCES, INC. (US) | 2015-08-05 | — | — | CN | disclosed |
| US-20140199316-A1 | METHODS OF TREATING COMPLICATIONS AND DISORDERS ASSOCIATED WITH G-CSF ADMINISTRATION | SACKSTEIN ROBERT (US) | 2014-07-17 | — | — | US | disclosed |
| US-8765126-B2 | Methods of treating complications and disorders associated with G-CSF administration | SACKSTEIN ROBERT (US) | 2014-07-01 | — | — | US | disclosed |
| US-20130224217-A1 | METHODS OF TREATING COMPLICATIONS AND DISORDERS ASSOCIATED WITH G-CSF ADMINISTRATION | SACKSTEIN ROBERT (US) | 2013-08-29 | — | — | US | disclosed |
| WO-2012151576-A1 | METHODS OF TREATING COMPLICATIONS AND DISORDERS ASSOCIATED WITH G-CSF ADMINISTRATION | SACKSTEIN ROBERT (US) | 2012-11-08 | — | — | WO | disclosed |
| EP-0064317-B1 | PYRROLO(2,3-D)CARBAZOLE DERIVATIVES, PREPARATION THEREOF AND THEIR THERAPEUTICAL USE | OMNICHEM Société anonyme (BE) | 1986-02-26 | — | — | EP | disclosed |
| US-4428880-A | Azepino[4,5-d]indole derivatives and preparation thereof | S.A. OMNICHEM (BE) | 1984-01-31 | — | — | US | disclosed |
| US-4362739-A | Pyrrolo(2,3-d)carbazole derivatives, compositions and use | S.A. OMNICHEM (BE) | 1982-12-07 | — | — | US | disclosed |
| EP-0064317-A2 | Pyrrolo(2,3-d)carbazole derivatives, preparation thereof and their therapeutical use | OMNICHEM Société anonyme (BE) | 1982-11-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140199316-A1 | METHODS OF TREATING COMPLICATIONS AND DISORDERS ASSOCIATED WITH G-CSF ADMINISTRATION | MPO, CSF3R, CSF1R | HTR2A 3775/4885HTR6 4477/4885SCN9A 4002/4885 |
| US-20210353763-A1 | SITE-SPECIFIC COVALENT CHEMICAL LIGATION TO MONOCLONAL AND POLYCLONAL IMMUNOGLOBULIN | FCGR3B, FCGR2A, FCGR1A | HTR2A 4084/4885HTR6 4174/4885SCN9A 4031/4885 |
| US-10588982-B2 | Site-specific covalent chemical ligation to monoclonal and polyclonal immunoglobulin | FCGR3B, FCGR2A, FCGR1A | HTR2A 4084/4885HTR6 4174/4885SCN9A 4031/4885 |
| US-20130224217-A1 | METHODS OF TREATING COMPLICATIONS AND DISORDERS ASSOCIATED WITH G-CSF ADMINISTRATION | MPO, CSF3R, CSF1R | HTR2A 3775/4885HTR6 4477/4885SCN9A 4002/4885 |
| US-20250354108-A1 | METHODS FOR PRODUCING MONOTERPENE INDOLE ALKALOIDS | INMT, KARS1, MIA3 | HTR2A 2339/4885HTR6 3067/4885SCN9A 4497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.